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Risk of suicide after suicide attempt according to coexisting
psychiatric disorder: Swedish cohort study with long term
follow-up
Dag Tidemalm,1 Niklas La˚ngstro¨m,2 Paul Lichtenstein,3 Bo Runeson4
ABSTRACT
Objective To investigate the impact of coexistent
psychiatric morbidity on risk of suicide after a suicide
attempt.
Design Cohort study with follow-up for 21-31 years.
Setting Swedish national register based study.
Participants 39685 people (53% women) admitted to
hospital for attempted suicide during 1973-82.
Main outcome measure Completed suicide during
1973-2003.
Results A high proportion of suicides in all diagnostic
categories took place within the first year of follow-up
(14-64% in men, 14-54% in women); the highest short
term risk was associated with bipolar and unipolar
disorder (64% inmen, 42% in women) and schizophrenia
(56% in men, 54% in women). The strongest psychiatric
predictors of completed suicide throughout the entire
follow-up were schizophrenia (adjusted hazard ratio 4.1,
95% confidence interval 3.5 to 4.8 in men, 3.5, 2.8 to 4.4
in women) and bipolar and unipolar disorder (3.5, 3.0 to
4.2 inmen, 2.5, 2.1 to 3.0 inwomen). Increased riskswere
also found for other depressive disorder, anxiety disorder,
alcohol misuse (women), drug misuse, and personality
disorder. The highest population attributable fractions for
suicide among people who had previously attempted
suicide were found for other depression in women
(population attributable fraction 9.3), followed by
schizophrenia in men (4.6), and bipolar and unipolar
disorder in women and men (4.1 and 4.0, respectively).
Conclusion Type of psychiatric disorder coexistent with a
suicide attempt substantially influences overall risk and
temporality for completed suicide. To reduce this risk,
high risk patients need aftercare, especially during the
first two years after attempted suicide among patients
with schizophrenia or bipolar and unipolar disorder.
INTRODUCTION
A suicide attempt is a risk factor for completed suicide;
the absolute risk in people followed-up for 5-37 years
was 7-13%,1-6 corresponding to a 30-40 times increased
risk of death from suicide in those who had attempted
suicide compared with the general population.7 The
impact of coexistent psychiatric morbidity on risk of
suicide after suicide attempts is largely unknown.
The interval between first communicationof suicidal
ideation or suicidal behaviour and completed suicide
varies with coexisting mental disorder; it is reportedly
shorter in depressive disorders than in personality and
psychotic disorders.8 We investigated the impact of
coexistent psychiatricmorbidity on risk of suicide after
a suicide attempt in a cohort of 39 685 people in
Sweden.
METHODS
We linked data on all 9.4 million people living in
Sweden during 1973-82 to the hospital discharge
register, cause of death register, 1970 population and
housing census, and education andmigration registers.
We identified people aged 10 or older who had been
admitted to inpatient care because of suicidal beha-
viour, defined as a definite suicide attempt or an
uncertain suicide attempt (n=49 509). In case of more
than one admission for a suicide attempt we used the
first admission as the index attempt. We excluded
people who had immigrated within two years before
baseline (n=860). Cases were those with one of the
studied psychiatric diagnoses at discharge from the
index admission or at discharge from the first inpatient
episode beginning within one week after this index
episode (n=12 681). Those without a diagnosis of
mental disorder within one year after the suicide
attemptwere used as reference subjects (n=27 004).We
did not include people with different psychiatric
diagnosis to those studied, or a diagnosis after one
week but within one year after the suicide attempt
(n=8964). The study cohort thus consisted of 39 685
people; 18 642 males and 21 043 females, mean age
38.4 (SD=16.5) years and 37.0 (SD 17.0) years. The
referencegroupcomprised68%of the studycohort and
consisted of people who had attempted suicide but had
none, subclinical, or milder forms of psychiatric
morbidity at the index episode and within one year
thereafter.
We studied eight psychiatric disorders: schizophre-
nia, bipolar and unipolar disorder, other depressive
disorder, anxiety disorder, adjustment disorder or
post-traumatic stress disorder, alcohol abuse or depen-
dence, drug abuse or dependence, and personality
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disorder. We introduced the potential confounders of
age, educational level, and immigrant status as
covariates in the regression analyses. We measured
education on a seven point ordinal scale.
Analyses
Patients were followed from discharge after attempted
suicide to a definite or uncertain suicide, death other
than suicide, first emigration, or end of follow-up (31
December 2003). Thus we followed-up patients for
21-31 years.
We used Kaplan-Meier survival curves to plot
temporal patterns of suicide after a suicide attempt;
we excluded adjustment disorder or post-traumatic
stress disorder owing to absence of risk effect and
substance misuse owing to low prevalence. For each
diagnostic category and sex we determined separately
absolute and relative mortality from suicide after a
suicide attempt and taking time at risk into account
used Cox regression models to compute hazard ratios
(95% confidence intervals). We adjusted the hazard
ratios for age,highest levelof education, and immigrant
status. For each psychiatric disorder we calculated the
population attributable fractions, expressing the
impact of coexistent psychiatric disorder on suicide
in people who had previously attempted suicide (see
bmj.com).We used SPSS forWindows (version 15) for
the statistical analyses.
RESULTS
Death from suicide occurred primarily within the first
five years after the index suicide attempt for all
diagnostic groups, including those without a psychiatric
diagnosis, but the risk prevailed over the follow-up
period (see bmj.com). A high proportion of all suicides
in each diagnostic group occurred within the first year
(table). People who had attempted suicide and had a
diagnosis of schizophrenia or bipolar and unipolar
disorder had a highly increased risk, especially in the
short term. For bipolar and unipolar disorder, 64% of
suicides in men and 42% in women occurred within the
first year; the corresponding proportions for schizo-
phrenia were 56% and 54%. The total mortality from
suicide in the reference group was comparatively low,
Absolute rates, hazard ratios, and population attributable fractions for death from suicide by psychiatric disorder in 39685 people who attempted suicide and
were admitted to hospital during 1973-82 in Sweden and followed to 2003
Diagnosis
Mean (SD) age at suicide
attempt (years)
Completed suicide within one year after
suicide attempt
Completed suicide during
entire follow-up
Suicide rate (%)
(No)
Proportion of all suicides
during follow-up (%)
Suicide rate (%)
(No)
Adjusted hazard
ratio* (95% CI)
Population
attributable fraction
Bipolar and unipolar disorder:
Male (n=395) 49.1 (16.4) 22.8 (90) 63.8 35.7 (141) 3.5 (3.0 to 4.2) 4.0
Female (n=648) 48.2 (15.4) 8.5 (55) 42.3 20.1 (130) 2.5 (2.1 to 3.0) 4.1
Other depressive disorder:
Male (n=1718) 40.4 (15.3) 6.0 (103) 37.7 15.9 (273) 1.4 (1.2 to 1.6) 3.1
Female (n=3364) 40.1 (15.7) 4.0 (135) 31.4 12.8 (430) 1.7 (1.5 to 1.9) 9.3
Schizophrenia:
Male (n=397) 34.1 (11.8) 21.7 (86) 56.2 38.5 (153) 4.1 (3.5 to 4.8) 4.6
Female (n=316) 38.7 (13.1) 13.0 (41) 53.9 24.1 (76) 3.5 (2.8 to 4.4) 2.8
Anxiety disorder:
Male (n=429) 35.0 (13.2) 8.2 (35) 41.2 19.8 (85) 1.9 (1.5 to 2.3) 1.6
Female (n=899) 34.9 (14.1) 3.3 (30) 30.3 11.0 (99) 1.5 (1.3 to 1.9) 1.7
Adjustment disorder or post-
traumatic stress disorder:
Male (n=244) 36.1 (14.6) 1.6 (4) 17.4 9.4 (23) 0.9 (0.6 to 1.3) −0.1
Female (n=520) 34.0 (14.4) 1.3 (7) 20.0 6.7 (35) 1.0 (0.7 to 1.4) 0.0
Alcohol abuse or dependence:
Male (n=2200) 41.2 (12.2) 2.7 (60) 20.4 13.4 (294) 1.1 (1.0 to 1.3) 1.1
Female (n=502) 39.2 (12.1) 1.8 (9) 14.3 12.5 (63) 1.7 (1.3 to 2.1) 1.4
Drug abuse or dependence:
Male (n=206) 32.2 (14.1) 2.4 (5) 13.5 18.0 (37) 1.6 (1.1 to 2.2) 0.6
Female (n=179) 34.8 (15.8) 2.8 (5) 16.7 16.8 (30) 2.3 (1.6 to 3.3) 0.9
Personality disorder:
Male (n=329) 31.8 (11.1) 5.2 (17) 26.2 19.8 (65) 1.8 (1.4 to 2.3) 1.2
Female (n=335) 30.8 (12.3) 2.1 (7) 19.4 10.7 (36) 1.5 (1.1 to 2.1) 0.6
Reference group:
Male (n=12 724) 37.9 (17.4) 5.1 (643) 45.1 11.2 (1426) Reference Reference
Female (n=14 280) 36.0 (17.6) 2.8 (402) 39.6 7.1 (1015) Reference Reference
Diagnoses were principal diagnoses assigned during an inpatient episode starting within one week after index suicide attempt.
*Hazard ratio for each coexistent psychiatric disorder compared with reference group (without any coexistent psychiatric disorder) category obtained with Cox regression modelling over total
follow-up period. Hazard ratios were adjusted for age, educational level, and immigrant status.
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although 45% of suicides in men and 40% in women
took place within the first year. Schizophrenia and
bipolarandunipolardisorderconferred thehighest risks
for suicide during the entire follow-up; hazard ratios
adjusted for age, education, and immigrant status
ranged from 2.5 for bipolar and unipolar disorder in
women to 4.1 for schizophrenia in men (table). Patients
with most other disorders had lower, but still signifi-
cantly increased, risks for suicide. Those with adjust-
ment disorder or post-traumatic stress disorder and
alcohol misuse (men only) did not have significantly
increased risks.
The highest population attributable fractions for
suicide among people who had previously attempted
suicide were for other depression in women (9.3),
schizophrenia in men (4.6), and bipolar and unipolar
disorder in women (4.1) and men (4.0).
DISCUSSION
Typeof coexistentpsychiatricmorbidity inpeoplewho
have previously attempted suicide is related to risk of
death from suicide. We investigated the risk for
completed suicide in patients who had attempted
suicide as a function of eight psychiatric disorders
and found substantial differences in risk across the
diagnoses. The rate of suicide after a previous suicide
attempt was particularly increased among both sexes
with schizophrenia or bipolar and unipolar disorder.
Population attributable fractions suggested a modest
but significant impact for other depression in women,
schizophrenia in men, and bipolar and unipolar
disorder in both sexes. The larger population attribu-
table fractions for these reflect their respective pre-
valence and the associated relative risk of suicide in the
study cohort. Thus other depressive disorder had a
comparatively high impact owing to its high preva-
lence, despite the risk of completed suicide not being as
high as for schizophrenia or bipolar and unipolar
disorder. As we only studied patients with previous
suicidal behaviour and controlled for age, education,
and immigrant status or ethnic minority group, hazard
ratios and population attributable fractions were
related to risks contributed by the mental disorder
itself, or some unmeasured confounders.
Death from suicide was heavily skewed towards the
first years after the suicide attempt particularly in
people with schizophrenia or bipolar and unipolar
disorder, probably because of symptom rich phases.
We expected a relatively high impact of substance
misuse or dependenceon risk of suicide1 but thehazard
ratio exceeded 2.0 only in females with drugmisuse or
dependencewhohad attempted suicide.Yetwe cannot
rule out the possibility that deaths in people with
physical stigma of substancemisuse are less likely to be
classified as suicide. Moreover, alcohol misuse could
be comorbidwith severaldisorders judgedasprincipal.
Anxiety disorder conferred a comparably increased
risk for suicide in both sexes. A complicating depres-
sion may be instrumental in risk of suicide in people
with anxiety disorder.9
By using an epidemiological framework and a total
population sample we tried to minimise selection bias
and power problems. The national cohort we followed
for at least 21 years is the largest with data on people
who have attempted suicide and on psychiatric
morbidity. Because the cause of death register has
excellent coverage, loss to follow-up should be
minimal. Limitations of our study were that we
included only people with suicide attempts that led to
an episode of inpatient care and we did not study the
contribution of physical illness4 10 and multiple psy-
chiatric comorbidity or analyse subcategories of the
diagnostic groups. Adjustment disorder or post-trau-
matic stress disorder was infrequently diagnosed
during 1973-82 and the size of this group might be
underestimated. Also, a narrow definition for bipolar
disorder was used in Sweden during the years of
inclusion; primarily for patients with more obvious
manic symptoms and similar to the type I diagnosis for
bipolar disorder from the Diagnostic and Statistical
Manual ofMentalDisorders, fourth edition. Furthermore,
among thedisorders labelledasmanicdepressive in the
international classification of disease, eighth revision,
the depressed type (296.2), which could be labelled
recurrent severe depression, contributed strongly to
the high risk of suicide in the bipolar and unipolar
group.We also defined coexistent psychiatric morbid-
ity as any disorder diagnosed within one week of the
suicide attempt. People who attempted suicide may
havebeendiagnosedas havingoneormorepsychiatric
disorders before or after this period, thereby resulting
in misclassification of patients with coexistent psychia-
tric morbidity as reference subjects. It is likely that
many subjects in the reference group had subclinical
psychiatric morbidity.
Specific treatment of patients who have attempted
suicide is often discussed on the basis of previous
suicide attempts11 and an estimate of suicidal intent.
Our results imply that interventions should take into
account coexistent mental disorder and the time that
has elapsed since the previous suicide attempt.
We thank Eva Carlstro¨m for data management.
Contributors: See bmj.com.
WHAT IS ALREADY KNOWN ON THIS TOPIC
A previous suicide attempt is a well established risk factor
for completed suicide
The impact of coexistent psychiatric morbidity on risk of
suicide after suicide attempts is largely unknown
WHAT THIS STUDY ADDS
Schizophrenia and bipolar disorder substantially influence
overall risk and temporality for completed suicide after a
suicide attempt in both sexes
Schizophrenia, bipolar and unipolar disorder, and other
depression have the strongest population impact on risk of
completedsuicide inpeoplewhohavepreviouslyattempted
suicide
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Hospital admissions for self harm after discharge from
psychiatric inpatient care: cohort study
David Gunnell,1 Keith Hawton,2 Davidson Ho,1,3 Jonathan Evans,4 Susan O’Connor,5 John Potokar,4
Jenny Donovan,1 Nav Kapur6
ABSTRACT
Objective To determine the risk of non-fatal self harm in
the 12 months after discharge from psychiatric inpatient
care.
Design Cohort study based on national hospital episode
statistics.
Setting England.
Population Patients aged 16-64 years discharged from
psychiatric inpatient care between 1 April 2004 and 31
March 2005 and followed up for one year.
Results 75401 people were discharged from psychiatric
inpatient care over the studyperiod, 4935 (6.5%)ofwhom
were admitted at least once for self harm in the following
12 months. Risk of self harm was greatest in the four
weeks after discharge; one third (32%, n=1578) of
admissions for self harm occurred in this period. The
strongest risk factor for self harm after discharge was
admission for self harm in theprevious12months (hazard
ratio 4.9, 95% confidence interval 4.6 to 5.2). The risk of
self harm was also higher in females, younger people,
those with diagnoses of depression, personality
disorders, and substance misuse, and those with short
lengths of stay.
ConclusionMore than 6% of patients discharged from
psychiatric inpatient care are readmitted for an episode of
self harm within 12 months, with one third of these
episodesoccurring in themonthafterdischarge.Self harm
after discharge from hospital shares many of the features
of suicide after discharge. Interventions should be
developed to reduce risk in this period.
INTRODUCTION
The risk of suicide in the month after psychiatric
inpatient care is around 100 times greater than that for
the general population.1-3 Although the high risk of
suicide shortly after discharge is well documented, less
is known about the rates of non-fatal self harm. Using
routine hospital discharge data for England we
investigated the incidence and timing of self harm in
the year after discharge frompsychiatric inpatient care.
METHODS
From the hospital episode statistics database for
England we selected all patients (n=75 401) aged
16-64 years who had been discharged from hospital
after general adult psychiatric care on at least one
occasion for the index year 2004-5.
We created a unique patient identifier from the
patient’s NHS number, postcode, date of birth, and
sex. This was used to search the database for 2004-5 and
2005-6 to identify readmissions within one year of
discharge,and for2003-4 to identifypreviousadmissions
for self harm or admissions to a psychiatric hospital.
We derived the main diagnosis for admission from
the international classification of diseases (10th revi-
sion): organic disorders, substancemisuse, schizophre-
nia and related psychoses, mania, depression and
anxiety, eating disorders, and other. The last category
comprised behavioural syndromes, disorders of adult
personality and behaviour, and unspecified diagnoses.
(See bmj.com for codes.) We classed readmissions for
self harm as intentional self harm, event of undeter-
mined intent, and accidental poisoning by exposure to
noxious substances (see bmj.com).
Analysis
WeusedCoxproportional hazards regressionmodels to
investigate the associations of age (16-24, 25-34, 35-44,
and 45-64), sex, diagnosis, and psychiatric admission or
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admissions for self harm in the year preceding the index
admission to a psychiatric hospital with the risk of being
readmitted with self harm in the year after discharge. If
patients were readmitted to a psychiatric hospital during
the follow-upperiodwe censored their data at the date of
readmission. Thus, if readmission for a psychiatric
disorder preceded readmission for self harm during
follow-up,weexcluded this episodeof self harmfromthe
analysis as it was likely to be related to the subsequent
admission. All records were censored after 52 weeks
follow-up. We fitted appropriate interaction terms to
investigate whether risk of self harm in relation to
diagnosis differed between men and women. We also
investigated whether the length of stay differed between
those who did or did not self harm.
As length of stay was highly positively skewed we
compared median length of stay for each diagnostic
group and used Wilcoxon’s rank sum test to compare
the lengths of stay of patients admitted or not admitted
to hospital for self harm in the year after discharge. To
assess whether any such associations were confounded
by differences in age and sex between those who did
anddidnot self harmweused log transformed lengthof
stay as the outcome variable in a linear regression
analysis to assess the effect of controlling for both these
factors in models.
RESULTS
Between 1 April 2004 and 31 March 2005, 75 401
patients were discharged from psychiatric inpatient
care in England (see bmj.com), of whom 11.7%
(n=8837) had been admitted to hospital for self harm
in the year before their index psychiatric admission.
Overall, 18 650 (24.7%) of those discharged were
readmitted to psychiatric bed within a year and 4935
(6.5%) were readmitted to a general hospital or
psychiatric bed for self harm. The risk of readmission
for self harmwas higher in females than inmales (8.0%
v 5.3%; χ2 216 (df=1); P<0.001).More than one third of
thosewhoself harmed (38.5%) afterdischargehadbeen
admitted to hospital for self harm in the year before
their index admission.
Risk of self harm diminished rapidly in the weeks
after discharge. One third (32.0%; 1578/4935) of
admissions for self harm occurred in the month after
Associations of sex, age, and psychiatric diagnosis with risk of self harm after discharge from inpatient psychiatric care
Risk factor No in sample
Hazard ratio
(95% CI) P value
Adjusted hazard ratio*
(95% CI) P value
Sex:
Male 40 751 1.00 1.00
Female 34 650 1.57 (1.49 to 1.66) P<0.001 1.40 (1.33 to 1.49) P<0.001
Age group (years):
16-24 10 149 1.00 1.00
25-34 19 185 0.91 (0.84 to 1.00) 0.96 (0.88 to 1.04)
35-44 22 263 0.85 (0.78 to 0.92) 0.86 (0.79 to 0.93)
45-64 23 804 0.63 (0.58 to 0.69) P<0.001 0.68 (0.62 to 0.75) P<0.001
Diagnosis:
Organic disorders (F00-F09) 561 1.26 (0.78 to 2.04) 1.47 (0.90 to 2.38)
Substance misuse (F10-F19) 12 948 3.00 (2.69 to 3.34) 2.64 (2.37 to 2.95)
Schizophrenia and related psychoses (F20-29) 18 513 1.00 1.00
Mania (F30, F31) 7655 1.23 (1.06 to 1.44) 1.17 (1.00 to 1.37)
Depression and anxiety (F32-F49) 17 905 3.74 (3.38 to 4.14) 2.69 (2.42 to 2.98)
Eating disorders (F50) 469 2.54 (1.74 to 3.69) 1.74 (1.19 to 2.53)
Other (F51-F69, F99) 6088 5.75 (5.14 to 6.44) 3.71 (3.31 to 4.17)
None of above codes 11 262 2.53 (2.26 to 2.84) P<0.001 2.16 (1.92 to 2.43) P<0.001
Psychiatric admission in year before index admission:
No 63 574 1.00 1.00
Yes 11 827 0.71 (0.65 to 0.78) P<0.001 1.25 (1.14 to 1.37) P<0.001
Admission for self harm in year before index admission:
No 66 564 1.00 1.00
Yes 8837 5.94 (5.61 to 6.29) P<0.001 4.85 (4.57 to 5.16) P<0.001
*Controlling for all variables in table.
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discharge, with 585 (11.9%) occurring within a week of
discharge; 2826 (57.3%) occurred within 12 weeks
(figure).
Although 1671 (33.9%) patients admitted for self
harm had a primary diagnosis of depression or anxiety
such patients comprised only 23.7% of those dis-
charged from hospital. In contrast, only 483 (9.8%)
patients admitted for self harm had a diagnosis of
schizophrenia and related psychoses at discharge,
whereas thiswas the commonest diagnosis at discharge
from psychiatric care (n=18 513, 24.6% of discharges).
In total, 688 (85.9%) of the 801 patients coded as
“other” who self harmed had personality disorder as
their primary diagnosis.
In fully adjusted models, risks were 40% higher in
females than inmales and declinedwith increasing age
—the risk of self harm after discharge was 32% (95%
confidence interval 25% to 38%) lower in those aged
45-64 than in those aged 16-24. The strongest risk
factor for self harmafter dischargewas anadmission for
self harm in the previous year (hazard ratio 4.85, 95%
confidence interval 4.57 to 5.16; table). The greatest
risks with specific diagnostic groups was for “other”
diagnoses, mainly personality disorder (hazard ratio
3.71), depression and anxiety (2.69), and substance
misuse (2.64). The apparent protective effect in
univariable models of previous psychiatric admission
(hazard ratio 0.71, 0.65 to 0.78) was because a
disproportionate number of those with a psychiatric
history had diagnoses of schizophrenia or psychosis
(38%) and this group are at reduced risk of self harm.
This effect was reversed (1.25, 1.14 to 1.37) in the
multivariable models controlling for a history of self
harm.
Across all diagnostic groups patients who self
harmed tended to have shorter hospital stays than
those who did not self harm (see bmj.com). In linear
regression models with log length of stay as the
outcome and controlling for age and sex, differences
in length of staywere little changed between thosewho
did and did not self harm.
DISCUSSION
At least 6% of people discharged from psychiatric
inpatient care in England self harm within a year. The
actual figure is likely to be higher as less than half the
episodes of self harm result in admission to hospital.4
One third of these episodesoccurredwithin amonth.A
higher proportion of females than males were read-
mitted with self harm (8.0% v 5.3%), and the risk was
greatest among people with depression, anxiety,
personality disorder, or substance use disorder and
lowest among those with schizophrenia and related
psychoses. An admission for self harm in the year
before the index psychiatric admission was the
strongest risk factor for self harm after discharge
(hazard ratio 4.85); one third of people admitted for
self harm after hospital discharge had been admitted
with self harm in the preceding year.
Strengths and limitations
This is a large study based on NHS hospital discharge
data for England. The hospital episodes statistics
database includes information on a patient’s NHS
numberanddateofbirth,whichenable readmissions to
be identified. Discharge diagnoses coded according to
the international classification of diseases (10th revi-
sion) allowedus to estimate the risks of self harm for the
main psychiatric diagnoses.
Our study has four main limitations. Firstly, as we
were only able to identify episodes of self harm leading
to hospital admission we will have underestimated the
magnitude of the problem. If the likelihood of
admission after presentation to hospital with self
harm differs by age, sex, and diagnosis then this will
bias our risk estimates. However, our results are likely
to reflect the more serious episodes of self harm.
Secondly, data in the database are collected for
administrative reasons and some patients may have
beenmiscoded; research indicates that the reliability of
these data for studies such as ours is reasonable.5
Thirdly, the range of personal data on the database is
relatively sparse—for example, information on occu-
pation is lacking. Lastly, we did not examine comor-
bidity,which is likely to be strongly associatedwith risk
of deliberate self harm and repetition after discharge,
norwerewe able to investigate the effect of aftercare on
risk of self harm.
Findings in relation to other studies
In keeping with our findings, a US based study found
that patients with personality disorder had the greatest
risk of self harm after discharge from psychiatric
inpatient care.6 In contrast with our findings, however,
no great increase in risk was found in the first 10 weeks
after dischargecomparedwith laterweeks.Thismaybe
because the authors relied on information from face to
face interviews and because response rates at the first
follow-up interview were only 74%.
Two studies investigated the risk of self harm among
adolescents discharged from psychiatric hospital.7 8
Both found that the risk was highest in the first few
WHAT IS ALREADY KNOWN ON THIS TOPIC
The risk of suicide in the month after discharge from
psychiatric care is about 100 times greater than that for the
general population
The incidence of non fatal self harm and risk factors for self
harm shortly after discharge are unknown
WHAT THIS STUDY ADDS
More than 6% of patients discharged from psychiatric
inpatient care were readmitted for self harm in the following
year, with a third occurring within one month
The strongest risk factor for self harmwas admission for self
harm in the year before psychiatric admission
The riskof self harmwashigher in females than inmales and
declinedwith increasing age and length of hospital stay and
is greatest in people with diagnoses of personality disorder,
depression, and substance misuse
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months after discharge, with risks of self reported self
harm of 12-20% in the year after discharge. It is likely
that these higher risks are due to both the increased
incidenceof self harmamongyoungpeople and theuse
of self report data.
Our findings of the high incidence of self harm in the
month after hospital discharge are in keeping with
those for suicide from other UK studies.1 2 9 In themost
recent analysis of data from the national confidential
inquiry 32% of suicides in the three months after
discharge occurred in the first two weeks9; in our study
the equivalent figure for self harm was 35% (1028/
2941). In studies of suicide after discharge from a
psychiatric hospital and our study of self harm after
discharge, rates among people with psychoses were
low compared with those for depression in analyses
based studies carried out in England1 and Scotland.2
Clinical implications
About 5%of deaths from suicide inEngland andWales
occur within three months of discharge from a
psychiatric hospital. Our analysis suggests that over
10% of patients may self harm after discharge and that
the risk is greatest in the firstmonth. Interventionsneed
to be developed to reduce this risk. Our findings
suggest that those patients who have self harmed
previously are at the greatest risk of self harm after
discharge. Other groups at increased risk include
females, young people, and those with diagnoses of
depression, personality disorder, and substance mis-
use, as well as people with short lengths of stay.
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expressed in this paper do not necessarily reflect those of the Department
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Maternal caffeine intake during pregnancy and risk of fetal
growth restriction: a large prospective observational study
CARE Study Group
ABSTRACT
Objective To examine the association ofmaternal caffeine
intake with fetal growth restriction.
Design Prospective longitudinal observational study.
Setting Two large UK hospital maternity units.
Participants 2635 low risk pregnant women recruited
between 8-12 weeks of pregnancy.
Investigations Quantification of total caffeine intake from
4weeksbeforeconceptionand throughoutpregnancywas
undertaken with a validated caffeine assessment tool.
Caffeine half life (proxy for clearance) was determined by
measuring caffeine in saliva after a caffeine challenge.
Smoking and alcohol were assessed by self reported
status and bymeasuring salivary cotinine concentrations.
Main outcome measures Fetal growth restriction, as
defined by customised birth weight centile, adjusted for
alcohol intake and salivary cotinine concentrations.
Results Caffeine consumption throughout pregnancy
was associated with an increased risk of fetal growth
restriction (odds ratios 1.2 (95% CI 0.9 to 1.6) for 100-
199 mg/day, 1.5 (1.1 to 2.1) for 200-299 mg/day, and
1.4 (1.0 to 2.0) for >300mg/day comparedwith <100mg/
day; test for trend P<0.001). Mean caffeine consumption
decreased in the first trimester and increased in the
third. The association between caffeine and fetal growth
restriction was stronger in women with a faster
compared to a slower caffeine clearance (test for
interaction, P=0.06).
Conclusions Caffeine consumption during pregnancy
was associated with an increased risk of fetal
growth restriction and this association continued
throughout pregnancy. Sensible advice would be to
reduce caffeine intake before conception and
throughout pregnancy.
This article is an abridged version
of a paper that was published on
bmj.com. Cite this article as: BMJ
2008;337:a2332
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INTRODUCTION
Maternal caffeine intake has been reported to be
associated with a reduction in birth weight,1-5 but the
level of intake above which the risk is increased
remains unknown.Caffeine intake of ≥300mg/day has
been associated with fetal growth restriction,6-8 but one
study foundasignificant reduction in infantweightwith
just 141 mg/day.9 More controversially, maternal
caffeine concentration has been to shown to have an
inverse association with birth weight when confoun-
ders such as smoking are taken into account.2 10 11
Caffeine is rapidly absorbed and crosses the placenta
freely. After ingestion of 200 mg caffeine, intervillous
blood flow in theplacentahasbeen found tobe reduced
by 25%.12 Cytochrome P450 1A2, the principal
enzyme involved in caffeine metabolism, is absent in
the placenta and the fetus. The amount of caffeine and
metabolites available to the fetoplacental unit therefore
depends on the maternal caffeine metabolism, which
shows marked variation between individuals. Varia-
tions in caffeine metabolic activity have been found to
bemore closely associatedwith fetal growth restriction
than have blood caffeine concentrations.13
We used a validated robust caffeine assessment tool
to quantify total caffeine intake from all possible
sources throughout pregnancy.14 Using these data,
and taking into account individual variation in
caffeine metabolism, we aimed to establish the safe
upper limit of caffeine consumption with respect to
adverse pregnancy outcome (specifically fetal growth
restriction).
METHODS
Participants
We prospectively recruited low risk pregnant women
at 8-12 weeks’ gestation from two large UK teaching
hospital maternity units (Leeds and Leicester) from
September 2003 to June 2006. Inclusion criteria
included age 18-45 years and singleton pregnancies,
dated by ultrasound. Demographic details were
recorded at baseline by means of a questionnaire.
Quantification of caffeine intake
Caffeine intake was estimated with a validated caffeine
assessment questionnaire which recorded habitual
caffeine intake before and during pregnancy, including
estimates of caffeine content from all potential dietary
sources and over the counter drugs, and details of
potential confounders such as smoking, alcohol intake,
and nausea (see bmj.com).14 Caffeine intake was
assessed throughout pregnancy by a caffeine assess-
ment tool administered three times: the first from four
weeks before pregnancy until recruitment into the
study; the second covered the period 13-28 weeks of
pregnancy; and the third included the period
29-40 weeks of pregnancy.
Saliva samples
Saliva samples for determining nicotine exposurewere
collected from women at recruitment. We assessed
caffeine half life from a caffeine challenge test
performed within two weeks of recruitment (see
bmj.com for details).
Risk of fetal growth restriction among offspring of 2635 pregnant women according to caffeine intake during pregnancy
Caffeine intake (mg/day)
Unadjusted risk* Adjusted risk†
Odds ratio (95% CI) Test for trend Odds ratio (95% CI) Test for trend
Average over pregnancy:
<100 1
P<0.001
1
P=0.02
100-199 1.2 (0.9 to 1.6) 1.2 (0.9 to 1.6)
200-299 1.6 (1.2 to 2.3) 1.5 (1.1 to 2.1)
≥300 1.8 (1.3 to 2.5) 1.4 (1.0 to 2.0)
In weeks 5-12:
<100 1
P<0.001
1
P=0.05
100-199 1.2 (0.9 to 1.6) 1.1 (0.8 to 1.5)
200-299 1.4 (1.0 to 2.0) 1.3 (0.9 to 1.9)
≥300 1.8 (1.3 to 2.5) 1.4 (1.0 to 1.9)
In weeks 13-28:
<100 1
P=0.001
1
P=0.02
100-199 1.5 (1.1 to 2.0) 1.4 (1.0 to 2.0)
200-299 1.8 (1.3 to 2.6) 1.7 (1.2 to 2.4)
≥300 1.6 (1.1 to 2.4) 1.3 (0.9 to 2.0)
In weeks 29-40:
<100 1
P<0.001
1
P=0.004
100-199 1.4 (1.0 to 1.9) 1.4 (1.0 to 2.0)
200-299 1.9 (1.3 to 2.8) 1.8 (1.2 to 2.7)
≥300 1.9 (1.3 to 2.8) 1.6 (1.0 to 2.4)
*Unadjusted odds ratios take account of maternal age, weight, height, ethnicity, and parity and neonatal gestational age at delivery and sex.
†Adjusted odds ratios are also adjusted for smoking status (salivary cotinine concentration) and alcohol intake.
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Pregnancy outcomes
We obtained information on antenatal pregnancy
complications and delivery details from the
electronic maternity databases. The primary out-
come measure was fetal growth restriction defined as
birth weight <10th centile on a customised centile
chart which takes into account maternal height,
weight, ethnicity, and parity and neonatal birth
weight and sex (www.gestation.net). We assessed
the association of maternal caffeine intake with
birth weight. Other pregnancy outcomes studied
were late miscarriage, preterm delivery, gestational
hypertension, proteinuric hypertension, and
stillbirth.
Statistical methods
From our sample size calculation, 3000 births were
required to give 80% power to detect a difference of
30 mg/day in caffeine intakes between mothers with
appropriate and growth restricted babies. Individual
caffeine consumption was expressed in mg/day
averaged over the whole pregnancy and for the
individual trimesters. We conducted logistic regres-
sion modelling for fetal growth restriction and
general linear modelling for birth weight, with
stratification for the two maternity units. Maternal
height, weight, ethnicity, and parity at booking and
neonatal gestation at delivery and sexwere taken into
account in the definition of fetal growth restriction
and were adjusted for in the model for birth weight.
We made statistical adjustments for salivary cotinine
levels and self reported alcohol consumption and
conducted sensitivity analyses to assess the robust-
ness of the results. Fromour caffeine challenge testwe
categorisedwomen as having a shorter half life (faster
caffeine clearance from the circulation) or longer half
life (slower clearance).We stratified the odds ratio for
fetal growth restriction by caffeine half life and intake
after taking account of potential confounders. (See
bmj.com.)
RESULTS
Over a period of three years, 13 071 eligible women
were invited to participate and 2635 (20%) consented.
See bmj.com for details of demographic and clinical
characteristics. The prevalence of fetal growth restric-
tion in the cohort was 343/2635 (13%). The mean
alcohol intake during pregnancy was 0.4 (95%
confidence interval 0 to 9) units/day, with the highest
consumption occurring before conception and during
the first four weeks of pregnancy.
Caffeine intake during pregnancy
The mean maternal caffeine intake during pregnancy
was 159mg/day. It decreased from238mg/day before
pregnancy to 139 mg/day between weeks 5 and 12 of
pregnancy and remained at about this level until the
third trimester, when it gradually increased to 153mg/
day. About 62% of the caffeine ingested by the women
during pregnancy was from tea. Other important
sourceswere coffee (14%), cola drinks (12%), chocolate
(8%), and soft drinks (2%). Hot chocolate, energy
drinks, and alcoholic drinks contributed 2%, 1%, and
<1% respectively. Over the counter drugs made a
negligible contribution to the total caffeine intake.
Relation between caffeine intake in pregnancy and fetal
growth
The relation between total caffeine intake in pregnancy
and fetal growth restriction showed a significant trend
with increasing caffeine intake (table). Caffeine con-
sumption of >200 mg/day during pregnancy was
associated with a reduction in birth weight of about
60-70 g, with a significant trend for greater reduction in
birthweightwith higher caffeine intake (P=0.004). This
relation was consistent across all three trimesters.
We analysed the relation between the estimated risk of
delivering a growth restricted fetus andmaternal caffeine
intake during pregnancy measured as a continuous
variable (figure). Therewas a rapid increase in associated
risk from increasing caffeine intake up to about 30 mg/
day. Thereafter, estimated risk continued to rise roughly
linearly in a dose-response relation. At no point did the
estimated risk cease to increase with increasing caffeine
intake. There was no observed plateau effect.
Relation between caffeine clearance and fetal growth
Using maternal caffeine half life as a proxy for
clearance rate, we found some evidence that the
association between caffeine intake and fetal growth
restrictionwas stronger in womenwith a faster caffeine
clearance than in those with slower clearance (test for
interaction, P=0.06).
Relation between smoking in pregnancy and fetal growth
Women classified as active smokers had nearly twice
the risk of fetal growth restriction compared with
women classified as non-smokers (adjusted odds ratio
1.9 (95% confidence interval 1.4 to 2.6), P<0.001). The
birth weights of babies born to active smokers were
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178 g lighter (95% confidence interval 127 to 230 g)
than those born to non-smokers (P<0.001).
DISCUSSION
Maternal caffeine intakewas associatedwith an increased
risk of fetal growth restriction even after adjustment for
smoking and alcohol intake. We could find no level of
intake at which there was no association with increased
risk of fetal growth restriction. The size of the association
for caffeine was of a similar size to that for alcohol intake
in pregnant women in this study (data not shown).
The strong association between caffeine intake and
birthweightwasmaintained across all of the trimesters.
However, from these results we cannot define a critical
time window for any maximal effect.
Strengths and weaknesses of the study
Although only 20% of the women we invited took part
in the study, this low response rate does not lessen
the validity of our data, as the association of caffeine
with birth weight should not be different from that in
the general population, especially as various confoun-
ders were taken into consideration. In addition,
examination of our maternity databases indicated
that the population we studied was similar to that of
the maternity units as a whole.
A strength is that we have objectively quantified
caffeine from all known sources. Since 26% of caffeine
intake in our cohort was from neither coffee nor tea,
studies that concentrated on coffee and tea alone will
underestimate caffeine intake.
Study results in comparison with other studies
Caffeineconsumptionalmosthalved inearlypregnancy.
The mean caffeine intake throughout pregnancy was
much lower than the recommended limit of 300 mg/
day.1516
Several studieshaveconcluded that caffeine intakeof
>300 mg/day is associated with low birth weight or
fetal growth restriction.6-8 We could find no level of
intake at which there was no associationwith increased
risk of fetal growth restriction, and this risk was
maintained throughout pregnancy. However, the
steep decline in risk associated with caffeine intakes
of <30 mg/day may be attributable to unmeasured
confounding. Although, the overall size of the reduc-
tion in birth weight may be seen as small, an extra
60-70 g inweight could reduce perinatalmorbidity and
mortality in an already compromised fetus.
We found that average caffeine consumption of
>100 mg/day was associated with a reduction in birth
weight of 34-59 g in the first trimester, 24-74 g in the
second, and 66-89 g in the third (after adjustment for
smoking status andalcohol intake). Similar resultswere
seen in a prospective US study, where mean birth
weight was reduced by 28 g for every 100 mg/day of
caffeine consumed, but the risk for fetal growth
restriction was unchanged.17
In a cohort of Danish women drinking at least three
cups of coffee a day before 20 weeks of pregnancy and
randomised to receive either caffeinated or decaffei-
nated instant coffee there was no significant difference
in birth weight between the two groups.18 However,
these women were recruited only in the second half of
pregnancy, and therewasnobiochemical confirmation
of participants’ compliance. No association was found
between maternal caffeine consumption and low birth
weight after adjusting for confounding variables in a
case-control study in Brazil.19
Caffeine metabolism
We complemented our assessment of caffeine intake
with a measure of caffeine metabolism and observed
that the association of caffeine intake with fetal growth
restriction was greater among women with faster
caffeine clearance. Caffeine is primarily metabolised
in the human liver to paraxanthine, but there are few
data about metabolism in pregnant women. (See
bmj.com for further discussion.)
Conclusion
This studyhasdemonstrated thatmaternalcaffeine intake
is associated with an increased risk of fetal growth
restriction. Our data confirm that the association of fetal
growth restriction with caffeine is reduced for those
consuming <100 mg/day. We suggest that sensible
advice for women contemplating pregnancy is to reduce
their caffeine intake from all sources before conception.
Once pregnancy is confirmed, they should make every
effort to stop or markedly reduce caffeine consumption.
We thank Gordon Gibson, Fred Kadlubar, and Mark Klebanoff for their
useful comments during the study. The Leicester team of the CARE Study
Group thank Vilas Misty, Clare Lawrence, Bhavin Daudia, and the
Department of Chemical Pathology, University Hospitals of Leicester N
HS Trust, for sample handling and processing.
See bmj.com for members of the CARE Study Group.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Caffeine is the most common xenobiotic consumed in
pregnancy, and there are conflicting results regarding the
association of increased caffeine intake in pregnancy with
fetal growth restriction and low birth weight
These differences could be explained by inconsistencies in
accurate quantification of caffeine and in the definition of
fetal growth restriction
WHAT THIS STUDY ADDS
Maternal caffeine intake isassociatedwithan increased risk
of fetal growth restriction after adjustment for smoking and
alcohol intake
The size of the association for caffeine intake with fetal
growth restriction is similar to that for alcohol intake
The association of caffeine with fetal growth restriction
seemstobestronger inwomenwith fastercaffeineclearance
Sensible advice to pregnant women would be to reduce
caffeine intake before conception and during pregnancy
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Drug use in children: cohort study in three European
countries
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ABSTRACT
Objective To provide an overviewof drug use in children in
three European countries.
Design Retrospective cohort study, 2000-5.
Setting Primary care research databases in the
Netherlands (IPCI), United Kingdom (IMS-DA), and Italy
(Pedianet).
Participants 675868 children aged up to 14 (Italy) or 18
(UK and Netherlands).
Main outcome measure Prevalence of use per year
calculated by drug class (anatomical and therapeutic).
Prevalence of “recurrent/chronic” use (three or more
prescriptions a year) and “non-recurrent” or “acute” use
(less than three prescriptions a year) within each
therapeutic class. Descriptions of the top five most
commonly used drugs evaluated for off label statuswithin
each anatomical class.
Results Three levels of drug use could be distinguished in
the study population: high (>10/100 children per year,
moderate (1-10/100 children per year), and low (<1/100
children per year). For all age categories, anti-infective,
dermatological, and respiratory drugswere in thehighuse
group, whereas cardiovascular and antineoplastic drugs
were always in the low use group. Emollients, topical
steroids, and asthma drugs had the highest prevalence of
recurrentuse, but relativeuseof lowprevalencedrugswas
more often recurrent than acute. In the top five highest
prevalence drugs topical inhaled and systemic steroids,
oral contraceptives, and topical or systemic antifungal
drugs were most commonly used off label.
Conclusion This overview of outpatient paediatric
prescription patterns in a large European population
could provide information to prioritise paediatric
therapeutic research needs.
INTRODUCTION
Recent years have seen growing concerns about the
incompleteness of the evidence relating to the efficacy
and safety of drugs used in children. Almost all of the
drugs prescribed to children are the same as those
originally developed for adults. They are often
prescribed on an unlicensed or “off label” basis
(percentages ranging from 11-80%1) simply by extra-
polating data for adults. Both the Food and Drug
Administration (FDA) and the European Medicines
Agency for the Evaluation of Medicinal Products
(EMEA) now offer extensions of drug licences to
companies who provide evidence concerning the
efficacy and safety in children of new drugs or off label
1Department of Medical
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drugs.2-5 We investigated the current use of paediatric
drugs in children in three European countries, using
population based data on primary care prescriptions.
METHODS
Data collection
We used the same protocol to study prescription
patterns in three countries: the UK, Netherlands and
Italy. We used the Pedianet database (paediatric
electronic medical records from 150 paediatricians
since 2000) in Italy, the integrated primary care
information (IPCI) database (comprising adult and
paediatric electronic medical records from more than
400 doctors since 1996) in the Netherlands, and the
IMS disease analyser database (IMS-DA: electronic
medical records on adults and children from 670
doctors) in the UK. All databases include the complete
automatedmedical records of primary care physicians
and have been used and proved valid for pharmaco-
epidemiological research.6 The age and sex distribu-
tion in the various databases is representative for the
country of origin.
Study population and drug prescriptions
The study population in each country consisted of all
children aged 0-18 years (0-14 years in Italy) who had a
databasehistoryof at least sixmonthsorwhowereborn
during the study period (1 January 2000 to 31
December 2005). We calculated the person time of
follow-up for each child, stratifiedby calendar year and
age group. Age was assessed on 1 January of each year
and grouped as <2, 2-11, and 12-18. Each child was
followed from the start of the studyperiodor thedate of
registration with the primary practice (whichever was
the latest) until the cancellation of registration with the
practice or the end of the study. We used the person
time accumulated in each calendar year as the
denominator to calculate prevalence rates. Over the
study period children could contribute to more than
oneage category.Thedrugprescriptionsweregrouped
on the basis of the WHO Anatomical Therapeutic
Chemical (ATC) classification system, which made
comparison between countries possible.
Statistical analysis
We estimated user prevalence rates (per 1000 person
years) by counting the number of children using a
specific drug in a specific calendar year. The pre-
valence rates were calculated by age and country.
For each anatomical class of drugwe assessed the age
and country specific user prevalence rates for all
individual drugs in 2005. We evaluated the five drugs
with the highest prevalence per anatomical class in
each country for off label status considering ageonly.A
drug was considered to be off label for age if the child’s
age at the time of use was below the lowest approved
age mentioned in the summary of product character-
istics of that drug in each country.7 We also identified
the treatments more commonly used for chronic than
acute paediatric diseases. See bmj.com.
RESULTS
Study population
Our population of 675 868 children generated
2 334 673 person years of follow-up; the mean indivi-
dual follow-up was 3.5 years. Most of the children
(66%) came from the IMS database in the UK, 19%
from Italy, and 15% from the Netherlands. The
databases recorded more than five million paediatric
prescriptions. In all three countries the prescription
rate was highest for the children aged under 2 and, in
each age group, was significantly higher in the UK and
Italy than in the Netherlands (P<0.001). See bmj.com.
Drug use by anatomical class
The highest prevalence rates among the children aged
under2were for anti-infectivedrugs, respiratorydrugs,
and dermatological drugs, which were used by 48%,
30%, and 30%of the children, respectively. Among the
children aged 2-11, the prevalence of use of anti-
infective, respiratory, and dermatological drugs
decreased to 30%, 21%, and 17%, respectively.
In adolescents (12-18 years), anti-infective, respira-
tory, anddermatological drugswere usedbymore than
10% per year.Most of the other drug classes were used
by 1-10%, but the prevalence of use of cardiovascular
and antineoplastic drugs was less than 1%.
In the youngest age groups, most of the drugs were
equally prescribed to both sexes or more commonly
prescribed to boys than girls (rate ratio <1). This
pattern reversed in adolescence, when user prevalence
for almost all drug classes (except non-sex hormones)
was higher among girls than boys. This sex pattern,
which was consistent across countries, was most
pronounced for genitourinary drugs, with a user
prevalence more than 60 times higher in girls because
they include oral contraceptives, which accounted for
95% of the use of genitourinary drugs in girls.
The age trend of prevalence of use was consistent
across countries, although there were some variations
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in the age specific rates (figure). See bmj.com for
details.
Prevalence of drug use in therapeutic class
Within the most commonly used anatomical drug
classes, antibacterial drugs accounted for most of the
anti-infective drug use; and the therapeutic classes,
antiasthmatic drugs, other respiratory products, and
nasal preparations were the most commonly used
drugs in the respiratory group. The therapeutic classes
with the highest prevalence of use among the
dermatological drugs were topical corticosteroids and
emollients and barrier creams.
When we ranked the therapeutic classes within each
anatomical class on the basis of the ratio between
recurrent (chronic) and non-recurrent (acute), we
observed a different pattern. In absolute terms,
emollients, topical corticosteroids, sex hormones,
anti-infectives, and drugs for obstructive airways
disease showed thehighest prevalenceof recurrent use.
Most commonly used off label drugs in each anatomical
class
Among the dermatological drugs the topical triazoles/
imidazoles were off label in most countries for at least
one ormore age categories. In the anti-infectives group
cefalexin (UK, <2 years) was the only off label drug.
Among the respiratory drugs, beclometasone, xylo-
metazoline, andcetirizinewereoff label in theyoungest
children (<2 years) in the UK and the Netherlands.
Among the most commonly prescribed alimentary
tract drugs ranitidine and laurilsulfate were off label in
children <2 years. For the genitourinary drugs, the
percentage of off label use of oral contraceptives and
antifungals was high in the Netherlands and the UK.
Among drugs for the nervous system, diazepam for
children under 12 in the Netherlands was off label. In
the group of sensory organ drugs the most commonly
prescribed drugs in the Netherlands (fusidic acid,
levocabastine) and the UK (chloramphenicol) were off
label. See bmj.com for details of the low prevalence
drugs that are off label.
DISCUSSION
We have provided a unique overview of primary care
prescriptionpatterns in a largemultinational European
paediatric population. The data could be used to
improve the prioritisation of research into long term
safety of paediatric drugs, as well as efficacy and
effectiveness studies in paediatric medicine. Off label
use in some of the most commonly and recurrently
used drugs is high (such as oral contraceptives) and
these should be considered for prioritisation.
Our data support the conclusions of the recently
published EMEA consensus/expert derived list of
research priorities concerning off patent medicinal
products,8 which emphasised the need for paediatric
studies of the safety of topical, systemic, and inhaled
steroids.EMEAalso lists topicalandsystemicantifungals,
acid reducing drugs, and antineoplastic drugs as research
priorities. These drugs are often or recurrently used and
are mostly off label. Sex hormones are not listed on the
priority list, whereas they are commonly and recurrently
prescribed, mostly off label. Further studies on the
efficacy and long term safety effects of these drugs in
young women are warranted.
Although patterns of drug use and labelling status can
inform decisions on prioritisation of research, these data
also inform us about suboptimal use and might even
uncover undesirable prescribing practices. For example,
fusidicacidandchloramphenicolareoftenusedandoften
off label for the treatment of conjunctivitis. Here the
emphasis should be on educating clinicians not to
prescribe rather than a call for more research.
Patterns of drug use
The percentage of off label use varied highly between
countries, and similar drugs differed in off label status
betweencountries.This confirms that thedifferences in
thepaediatric statusof thedrugs, insteadof thedifferent
prescription habits ormedical cultures as postulatedby
many authors, represent the real reason for the
variability reported by years and frommanyEuropean
studies and surveys on the off label use in children.9
Previous studies
Previous European studies have been country or region
specific and have concentrated on specific conditions,
except for studies from Sweden, the Netherlands, and
Denmark in the late 1990s and a recent Italian study
covering data from 2000-6.10-13 These studies took all
types of drugs into account but the methods to calculate
prevalence and ranking and age ranges varied largely,
which complicates direct comparisons. The overall
results—highest drug use in lowest age category, ranking
of the most commonly used drugs, and sex pattern are
consistent with our findings.101415
WHAT IS ALREADY KNOWN ON THIS TOPIC
Most previous research on drug use in children has focused
on specific high use areas such as antibiotics and
respiratory and neuropsychiatric drugs, therefore most of
these drugs have a paediatric licensing status
Paediatric expert groups have been established by the
European Medicines Evaluation Board (EMEA) to identify
thosedrugs that are important for the paediatric community
and that require additional efficacy and safety data
WHAT THIS STUDY ADDS
Data on frequency of prescriptions and off label status of
drugs could provide objective evidence for the prioritisation
of research in paediatric drugs
Information on the safety and efficacy of some of the most
commonly used drugs in children (such as oral
contraceptives, steroids, and triazoles/imidazoles) is
lacking, and not all such drugs are on the list of research
needs
RESEARCH
1340 BMJ | 6 DECEMBER 2008 | VOLUME 337
Limitations
We captured only outpatient, primary care drug
prescriptions and not use of over the counter drugs.
Drugs given in hospital and the monitoring of
chemotherapeutic and biological drugs are unlikely
to be fully captured by our databases. As the UK
accounted for 60% of the study population the pooled
results are dominated by UK prescription patterns so
we conducted stratified analyses as much as possible.
Finally, we studied drug prescriptions rather than drug
intake, and so the prevalence of actual drug exposure
might be lower than estimated here.
We thank Peter Stephens of IMS Health for providing the IMS-DA database
and all the physicians contributing data to the databases.
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Test, episode, and programme sensitivities of screening for
colorectal cancer as a public health policy in Finland:
experimental design
Nea Malila,1 Tiina Oivanen,2 Outi Malminiemi,3 Matti Hakama1,4
ABSTRACT
Objectives To report the sensitivities of the faecal occult
blood test, screening episode, and screening programme
for colorectal cancer and the benefits of applying a
randomised design at the implementation phase of a new
public health policy.
Design Experimental design incorporated in public health
evaluation using randomisation at individual level in the
target population.
Setting 161 of the 431 Finnish municipalities in 2004-6.
Participants 106000 adults randomised to screening or
control arms. In total, 52 998 adults aged 60-64 in the
screening arm received faecal occult blood test kits.
Main outcome measures Test, episode, and programme
sensitivities estimated by the incidence method
and corrected for selective attendance and
overdiagnosis.
Results The response for screening was high overall
(70.8%), and significantly better in women (78.1%) than
in men (63.3%). The incidence of cancer in the controls
was somewhat higher in men than in women (103 v 93
per 100 000 person years), which was not true for
interval cancers (42 v 49 per 100 000 person years).
The sensitivity of the faecal occult blood test was
54.6%. Only a few interval cancerswere detected among
those with positive test results, hence the episode
sensitivity of 51.3% was close to the test sensitivity. At
the population level the sensitivity of the programme
was 37.5%.
Conclusions Although relatively low, the sensitivity of
screening for colorectal cancer with the faecal occult
blood test in Finland was adequate. An experimental
design is a prerequisite for evaluation of such a
screening programme because the effectiveness of
preventing deaths is likely to be small and results may
otherwise remain inconclusive. Thus, screening for
colorectal cancer using any primary testmodality should
be launched in a public health programme with
randomisation of the target population at the
implementation phase.
This article is an abridged version
of a paper that was published on
bmj.com. Cite this article as: BMJ
2008;337:a2261
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INTRODUCTION
Screening for colorectal cancer using the faecal occult
blood test has been shown to reduce mortality in four
randomised screening trials,1-4 but effectiveness at
reducing mortality has not been shown routinely
within a public health policy. Finland started an
organised screening programme for colorectal cancer
in 2004, with individuals randomised at implementa-
tion of the programme. Although the effect on
mortality will not be known for several years we
monitored the programme using intermediate indica-
tors. We estimated the sensitivity of screening in
identifying unrecognised disease at the level of the
faecal occult blood test, screening episode, and
programme. We also determined the benefits of the
experimental design using randomisation at the
implementation phase.
METHODS
The screening programme was started in September
2004 in 22 volunteer municipalities. Randomisation at
individual level into screening and control groups was
done at the first screening round, in adults aged 60, 62,
and 64. By 2006, the programme covered 161 of the
431 municipalities in Finland.
The population was sampled through the Popula-
tion Register Centre, which keeps records and
personal identifiers on every Finnish citizen. After
sampling from the population register, people were
stratified into groups according to municipality, year
of birth, and sex.Within each groupparticipantswere
alternately randomly allocated to screening or con-
trol groups. Those in the screening arm were invited
to respond by post; those in the control arm were
identified but not contacted.
A national screening centre was established in
Tampere at the local cancer society to deal with the
invitations, responses, and recommendations for
referrals and to analyse the faecal samples. Faecal
occult blood test kits (Hemoccult; Beckman Coulter,
USA)wereposted to thoseoffered screeningalongwith
an invitation to the programme and advice on taking
the sample. The centre analysed the kits and posted the
findings to the respondents independently of the result.
If bloodwasdetected in the sample, the respondentwas
given the contact details of their health centre.
Simultaneously, a letter was sent to the health centre
for colonoscopy to be arranged.
The aim of screening for cancer is to detect the
disease in the preclinical (unrecognised) phase. We
estimated sensitivity at the level of the test, screening
episode, and programme.5 Test sensitivity measures
how well the test identifies the disease in the
preclinical phase, episode sensitivity also takes into
account the diagnostic confirmation after a positive
test result, and programme sensitivity indicates the
proportion of patients with cancers in the target
population detected by screening.We corrected each
of these estimates for bias caused by overdiagnosis
and selective attendance.5 (See bmj.com for formulas
used to determine sensitivities.)
We estimated sensitivity using the incidence
method.6 No direct observation of the disease in the
detectable preclinical phase is available, and there-
fore estimates were based on the failure of screening.
To estimate the proportion of false negative test
results we measured failure by the incidence of
interval cancer (incidence of colorectal cancer
between two screening rounds) and compared this
with the incidence of colorectal cancer in the control
arm and in non-responders.
We estimated the incidence rates for people invited
to take part in the first round of screening and for
controls from 2004-6. Follow-upwas through routine
measures by the cancer registry. The latest linkage
was in June 2008, when cancers diagnosed in 2007
had almost been reported to the registry. Follow-up
started from the date of random sampling, including
linkage of postal addresses. Follow-up ended at the
date of the next (second round) linkage of addresses,
the date of diagnosis of colorectal cancer, or 31
December 2007 (latest date with follow-up for
cancer), whichever came first. Screening is offered
every second year, but owing to differences between
municipalities, the first screening interval varied
between 1.5 and 2.7 years. In case linkage for the
second round had not been done by the end of 2007
(those in the first round in 2006), the follow-up ended
on 31 December 2007. In addition, 2461 people
missed the second round and therefore, for these
individuals follow-up ended after two years. We
recorded the number of colorectal cancers diagnosed
during follow-up. Patients with colorectal cancer
already diagnosed before random sampling or at the
first screen and those with a date of diagnosis as the
month of random sampling did not contribute to
follow-up time in the analysis. We excluded from the
estimation of incidence of interval cancer, patients
with cancer but no follow-up time and screen
detected cancers.
RESULTS
Overall, 106 000 adults were randomised in 2004-6:
52 998 to screening and 53 002 to the control arm (see
Sensitivities in Finnish screening programme for colorectal cancer, 2004-6
Indicator (%) Men Women Total
Test sensitivity 61.8 47.8 54.6
Episode sensitivity 57.1 45.8 51.3
Programme sensitivity 39.0 36.0 37.5
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bmj.com). Attendance was 70.8%, better in women
than in men (78.1% v 63.3%). Of 806 people with a
positive test result 65 had a diagnosis of cancer (see
bmj.com). During a mean follow-up of 1.9 years, 35
interval cancers and 26 cancers in non-responders
were diagnosed (see bmj.com). Of the interval
cancers, 32 were in people who tested negative and
three in those who tested positive but with a negative
colonoscopy result. The number of colorectal can-
cers diagnosed in the control population was 98
during a mean follow-up of 1.9 years.
Incidence of colorectal cancer in the control
population was 98 per 100 000 person years and the
incidence of interval cancer in those with a negative
result at first screening episode was 49 per 100 000
person years (see bmj.com). About every second case
of colorectal cancer in the preclinical phase was
identified by the test (test sensitivity 54.6%; table).
The incidence of cancer in the controlswas somewhat
higher in men than in women (103 v 93 per 100 000
person years), which was not true for interval cancers
(42 v 49 per 100 000 person years). Only three
interval cancers were diagnosed among those with a
positive test result but no cancer at colonoscopy.
Therefore episode sensitivity at 51.3% was close to
test sensitivity. Despite a high attendance rate
programme sensitivity remained low (37.5%).
DISCUSSION
We found high attendance in the screening pro-
gramme for colorectal cancer that was run as a public
health policy in Finland. The faecal occult blood test
was able to detect amajor proportion (55%)of cancers
in the detectable preclinical phase andmore than one
third (38%) in the total target population.
With screening every two years using the faecal occult
blood test the reduction in mortality from colorectal
cancer varies between 25% at 18 years7 and 12% at eight
years.4 In one trial with a follow-up of 18 years, a 20%
reduction in incidence of colorectal cancer was also
seen.8 Several organisations therefore recommend
screening for colorectal cancer as a public health
policy.9 Finland was, to the best of our knowledge, the
first country to start a national screening programme.
Public health policies that include screening are
generally evaluated by non-experimental means. Such
approaches are likely to result in inconclusive evidence,
especially if the effect is expected tobe small.10Therefore
a sensitive andunbiaseddesign including randomisation
at the implementation phase of the programme was
chosen in Finland.11
We investigated the sensitivity of the colorectal cancer
screening programme at the level of the faecal occult
blood test, screening episode, and programme. Tradi-
tionally, sensitivity has been regarded as an indicator of
the test.
Test sensitivity and episode sensitivity could be
expected to be identical, because colonoscopy is
considered the ideal investigation in the diagnosis of
colorectal cancer. This was not true, however, even if
the sensitivities were close (54.6% and 51.3%).
Experts in many countries expressed concern about
sufficient capacity for colonoscopy from routine
screening with the faecal occult blood test.12 This
was not a problemas the 2% test positivity rate did not
radically increase the need for resources. Instead,
proper targeting may reduce the number of unneces-
sary colonoscopies in the future.
The response rate in Finland was relatively high
(70.8%), especially in women (78.1%). The sensitivity
of the programme remained low, however, at 37.5%,
similar in both sexes. It has been proposed that
screening in women should be started at an older age
than in men to give a similar yield.13
Limitations
Follow-up in this study was for a mean 1.9 years,
slightly less than one full screening interval. As
reliable data on cancer incidence were available only
until the end of 2007, some people randomised in
2006 were followed-up for only part of the full
interval at the end of follow-up in December 2007.
However, the mean follow-up time for those starting
in 2006 was 1.7 years. If anything, the completed
follow-up data up to two years is likely to show a
decrease rather than an improvement in the sensitiv-
ity estimates, since the incidence of interval cancer in
the first interval is at its highest close to the second
round.
Not all cancers diagnosed in Finland in 2007 had
been reported to the cancer registry by the time of
linkage in June 2008. We estimated the number of
possiblemissing cases from the first screening roundby
comparing data on screen detected cases from the
screening centrewith the files of the cancer registry.No
cases of colorectal cancerwere unknown to the registry
from the first screening round in 2004-6, with
diagnostic confirmation done by the end of 2007.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Randomised controlled trials using faecal occult blood tests
to screen for colorectal cancer have shown a reduction in
mortality in those invited compared with controls
Several countries have started screening, many as
spontaneous activity or non-organised screening
Many organisations recommend screening through public
programmes although no conclusive evidence on their
effectiveness is available
WHAT THIS STUDY ADDS
Four of 10 cases of colorectal cancer were detected by a
public screening programme in Finland
This programme provides a model on how to implement a
new screening programme using the principles of
experimental design with randomisation to obtain
conclusive evidence on effectiveness
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Implications
The sensitivity of the Finnish screening programme at
the first roundwas adequate even if relatively low. Two
trials reportedepisode sensitivities only,1 3 at 49.5%and
44.2%. Although the analyses of those trials are not
comparable with ours, it seems that our episode (and
test) sensitivities are slightly higher than those from the
trials in the United Kingdom and Denmark.
A rigorous design is a prerequisite for evaluating the
process and the effectiveness of the programme on the
number of deaths prevented from colorectal cancer.
Thus routine primary screening for colorectal cancer
should only be launched as an organised programme,
including randomisation at the implementation phase.
We thank Minna Merikivi and Hilkka Laasanen from the Finnish cancer
registry for coding and linking cases of colorectal cancer among the study
population, the steering committee of the colorectal cancer screening
programme at the Cancer Society of Finland, and the steering committee
for screening of the Ministry of Social Affairs and Health, Finland for advice
and administrative support in the planning of the programme.
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Diogenes syndrome
Diogenes syndrome, otherwise known as senile self
neglect syndrome, is used to describe an older adult living
in squalor but with no sign of mental or cognitive
impairment sufficient to explain the self neglect. Some
commentators have written that the squalor and hoarding
are just signs of obsessive-compulsive disorder, dementia,
or other mental disorder, but most workers in older adult
psychiatry will have seen plenty of cases with no
explanatory psychiatric disorder.
Alternatively, Diogenes syndrome may simply be a
description of a social situation. This would fit with my
impression that referrals for Diogenes syndrome have
tailed off since reality television programmes started
showingcelebrity cleaning ladies helping “normal”people
living in squalor. Age seems to be a factor: perhaps it is a
sign of our paternalistic culture that a person younger than
65 living in squalor is seen by millions on television,
whereas those past the age of 65 are seen by a psychiatrist.
The title Diogenes syndrome, proposed in Clark and
others’ original study from 1975,1 is at least as controversial
as the condition itself. There were at least four philosophers
of note with that name, but the syndrome is named after
Diogenes of Sinope,who famously lived in a barrel.Clark et
al gave a potted biography of Diogenes but did not spell out
exactlywhy they chose toname thecondition afterhim.The
OxfordTextbook ofOlder AgePsychiatryhasdescribed thename
as “inept,” and the latest edition gives alternatives better
suited to describing the squalor.2
If we think of Diogenes syndrome purely in terms of
housekeeping, then the label does seem presumptuous.
Diogenes supplied his day to day needs by begging and
had an unconventional home, but for all we know he may
have kept the barrel spick and span, dusting obsessively
while pondering the mysteries of the universe.
There is, however, another aspect to the Diogenes
story. Diogenes helped found the Cynic movement,
which preached a defiance of social conventions. Clark
et al’s biography does mention en passant that Diogenes
was renowned for his “lack of shame” and “contempt for
social organisation.” It is said that Alexander the Great
went to meet Diogenes and asked him if there was
anything he could do for him. Diogenes squinted at the
most powerful man in the ancient world and replied yes,
could he move over a bit as he was blocking the
philosopher’s sunlight.
This side of the Diogenes story will strike a chord with
many psychiatrists who find themselves caught between
angry relatives, bewildered social workers, and an
independent older adult contemptuous of a society
obsessed with risk. Perhaps a syndrome deserves to be
named afterDiogenes after all, not to emphasise the dirt or
neglect, but rather in celebration of frail elderly people
who choose to cock a snook at doctors, social workers, and
a society that tries to tell them what to do with their lives
just because of their age. Diogenes, by the way, lived to a
ripe old age.
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